Steffan N. Ho is Vice President and Head of Translational Oncology in the Pfizer Oncology Division, where he leads a team of highly engaged clinical translational scientists focused on collaborating with urgency to translate our understanding of cancer biology and advances in technology into new medicines for patients with cancer. As a board-certified pathologist and principal research investigator with over 25 years of clinical, academic, and industry experience, Dr. Ho provides leadership that brings together an understanding of clinical diagnostics, human cancer, tumor biology, immunology, precision medicine, technology platforms, and drug development. He has contributed to translational oncology efforts supporting the approval of a broad spectrum of small molecule and biologic medicines as well as a number of companion diagnostic tests benefiting patients with solid tumor and hematologic malignancies.
Prior to Pfizer, Dr. Ho was on the faculty at the University of California at San Diego in the School of Medicine before transitioning into drug development at Biogen Idec, where he led a discovery research team and established a clinical translational oncology group. Dr. Ho grew up in Minnesota, where he received his undergraduate degree from Carleton College and his M.D. and Ph.D. degrees from the Mayo Clinic. He went on to complete postgraduate medical training and postdoctoral research at the Stanford University School of Medicine.
